×
About 9,408 results

ALLMedicine™ Hypertrophic Cardiomyopathy Center

Research & Reviews  3,332 results

Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Card...
https://doi.org/10.1177/10600280221117812
The Annals of Pharmacotherapy; Dalo JD, Weisman ND et. al.

Aug 12th, 2022 - To assess mavacamten's role in hypertrophic cardiomyopathy treatment. In addition to clinical guidelines, package inserts, and general reviews, we searched PubMed using the term mavacamten from inception to June 11, 2022. English language studies ...

Use of a Spinal-Caudal Epidural Technique for Abdominal Surgery in a Newborn With Noona...
https://doi.org/10.1213/XAA.0000000000001611
A&A Practice; Couser DF, Veneziano GC et. al.

Aug 12th, 2022 - Features of Noonan syndrome include a distinctive facial appearance, short stature, a broad or webbed neck, congenital heart disease, bleeding problems, skeletal malformations, and developmental delay. Although pulmonary stenosis is most commonly ...

Prognostic value of age-sex adjusted NT-proBNP ratio in obstructive hypertrophic cardio...
https://doi.org/10.1016/j.pcad.2022.08.002
Progress in Cardiovascular Diseases; Hutt E, Mentias A et. al.

Aug 12th, 2022 - We sought to determine the incremental prognostic value of age-sex adjusted N-terminal prohormone brain natriuretic peptide (NT-pro BNP) ratio in obstructive hypertrophic cardiomyopathy (oHCM) patients. The study included 2119 consecutive oHCM pat...

Pseudohypoaldosteronism associated with hypertrophic cardiomyopathy, hypertension and t...
https://doi.org/10.1515/jpem-2021-0626
Journal of Pediatric Endocrinology & Metabolism : JPEM; Mendes LC, de Oliveira Magalhães R et. al.

Aug 11th, 2022 - PHA1 is a rare heterogeneous disorder featured by changes in renal electrolyte transport due to mineralocorticoid resistance. The aim of the current study is to report the case of a child with 5-year follow-up presenting mutation in the ElaC Ribon...

Mitral chordal rupture in obstructive hypertrophic cardiomyopathy visualized using four...
https://doi.org/10.1093/ehjci/jeac158
European Heart Journal. Cardiovascular Imaging; Akita K, Suwa K et. al.

Aug 10th, 2022 - Mitral chordal rupture in obstructive hypertrophic cardiomyopathy visualized using four-dimensional flow cardiac magnetic resonance imaging.|2022|Akita K,Suwa K,Iguchi K,Ushio T,Maekawa Y,|

see more →

Guidelines  10 results

Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic ...
https://doi.org/10.1016/j.echo.2022.03.012
Journal of the American Society of Echocardiography : Off... Nagueh SF, Phelan D et. al.

Jun 7th, 2022 - Hypertrophic cardiomyopathy (HCM) is defined by the presence of left ventricular hypertrophy in the absence of other potentially causative cardiac, systemic, syndromic, or metabolic diseases. Symptoms can be related to a range of pathophysiologic ...

2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic ca...
https://doi.org/10.1016/j.jtcvs.2021.04.001
The Journal of Thoracic and Cardiovascular Surgery; , Ommen SR et. al.

May 1st, 2021 - 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.|2021| ,Ommen SR,Mital S...

ACR Appropriateness Criteria® Nonischemic Myocardial Disease with Clinical Manifestatio...
https://doi.org/10.1016/j.jacr.2021.01.019
Journal of the American College of Radiology : JACR; , Rajiah P et. al.

Mar 3rd, 2021 - Nonischemic cardiomyopathies encompass a broad spectrum of myocardial disorders with mechanical or electrical dysfunction without evidence of ischemia. There are five broad variants of nonischemic cardiomyopathies; hypertrophic cardiomyopathy (Var...

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Ca...
https://doi.org/10.1016/j.jacc.2020.08.045
Journal of the American College of Cardiology; Ommen SR, Mital S et. al.

Nov 25th, 2020 - 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.|2020|Ommen SR,Mital S,B...

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Ca...
https://doi.org/10.1016/j.jacc.2020.08.044
Journal of the American College of Cardiology; Ommen SR, Mital S et. al.

Nov 25th, 2020 - This executive summary of the hypertrophic cardiomyopathy clinical practice guideline provides recommendations and algorithms for clinicians to diagnose and manage hypertrophic cardiomyopathy in adult and pediatric patients as well as supporting d...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  176 results

Prospective Evaluation Of Exercise-Induced Cardiac Conduction Instability In Predicting Ventricular Fibrillation Events In Hypertrophic Cardiomyopathy
https://clinicaltrials.gov/ct2/show/NCT04157205

Aug 10th, 2022 - To find out how accurate V-CoS test is the investigator will study patients with confirmed Hypertrophic Cardiomyopathy currently thought to be high risk. They will be tested by V-CoS and have their conventional risk score worked out. Patients will...

CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM
https://clinicaltrials.gov/ct2/show/NCT05186818

Aug 10th, 2022 - The purpose of this study is to evaluate the efficacy and safety of aficamten (CK-3773274) in adults with symptomatic hypertrophic cardiomyopathy and left ventricular outflow tract obstruction

OPIE in the Thin Interventricular Septum
https://clinicaltrials.gov/ct2/show/NCT04050579

Aug 10th, 2022 - This is a follow up investigation to our previous study entitled "On-pump intraoperative echocardiography (OPIE)" (clinicaltrials.gov NCT03094325) whereby we determined that left ventricular septal thickness as measured by the OPIE technique corre...

A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
https://clinicaltrials.gov/ct2/show/NCT03442764

Aug 9th, 2022 - This is a multicenter, exploratory, randomized, double-blind study of the administration of mavacamten in 60 participants with symptomatic nHCM randomized to receive a 16-week course of mavacamten doses titrated to achieve 1 of 2 target drug conce...

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstru...
https://clinicaltrials.gov/ct2/show/NCT05489705

Aug 5th, 2022 - The purpose of this study is to evaluate the safety of mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) treated in the real-world setting. The registry study also provide a real-world understanding of the curre...

see more →

News  222 results

May 13, 2022 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/973900

May 13th, 2022 - Please note that the text below is not a full transcript and has not been copyedited. For more insight and commentary on these stories, subscribe to the This Week in Cardiology podcast on Apple Podcasts, Spotify, or your preferred podcast provider...

FDA Clears Mavacamten (Camzyos) for Obstructive Hypertrophic Cardiomyopathy
https://www.medscape.com/viewarticle/972945

Apr 29th, 2022 - The US Food and Drug Administration (FDA) has approved mavacamten (Camzyos, Bristol Myers Squibb) to improve functional capacity and symptoms in adults with symptomatic New York Heart Association (NYHA) class II to III obstructive hypertrophic car...

Fast Five Quiz: Hypertrophic Cardiomyopathy
https://www.medscape.com/viewarticle/969363

Apr 13th, 2022 - Hypertrophic cardiomyopathy (HCM) is a genetic disease of the heart characterized by an increase in left ventricular wall thickness (≥ 15 mm) in the absence of abnormal loading conditions (hypertension, congenital heart disease, or valvular diseas...

Fast Five Quiz: Hypertrophic Cardiomyopathy Workup
https://www.medscape.com/viewarticle/969366

Apr 13th, 2022 - Hypertrophic cardiomyopathy (HCM) is a genetic disease of the heart characterized by an increase in left ventricular wall thickness (≥ 15 mm) in the absence of abnormal loading conditions (hypertension, congenital heart disease, or valvular diseas...

Mavacamten controlled hypertrophic cardiomyopathy for over 1 year
https://www.mdedge.com/cardiology/article/253404/heart-failure/mavacamten-controlled-hypertrophic-cardiomyopathy-over-1
Mitchel L. Zoler, PhD

Apr 3rd, 2022 - WASHINGTON – Treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy who remained on treatment with the investigational agent mavacamten for a median of 62 weeks continued to show the same level of safe response to the drug.

see more →

Patient Education  13 results see all →